Minocycline for people having a stroke who receive clot-dissolving treatment through a vein
Tests minocycline against placebo in adults with acute ischaemic stroke receiving thrombolysis.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis
Key facts
- Where
- Beijing and Liaocheng, ChinaSee the 3 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with an acute ischaemic stroke who get, or will get, clot-dissolving treatment through a vein. It tests whether minocycline helps recovery.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Acute ischaemic stroke confirmed by CT or MRI. Stroke severity (NIHSS score) must be between 6 and 25, with item Ia of 1 or less.
- Earlier treatment
- Intravenous thrombolysis (alteplase, tenecteplase, reteplase or recombinant human prourokinase) given or planned within 4.5 hours of onset, or within 4.5-24 hours based on guidelines. The study drug is given before it or within 2 hours after it starts.
Main reasons for not taking part
- mRS score of 2 or more before this stroke
- Allergy to tetracycline antibiotics or minocycline, or tetracycline use in the past 7 days
- Infection needing antibiotics
- Bleeding in the brain in the past 3 months
- Severe liver or kidney problems, or dialysis before randomization
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07526987, who can take part
Where in China
- Beijing Tiantan HospitalBeijing, ChinaNot yet recruiting
- Guanxian People's HospitalLiaocheng, ChinaTaking people
- Liaocheng Third People's HospitalLiaocheng, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07526987
- Record updated
- 1 July 2026
- Original description
The aim of this study is to assess the efficacy and safety of minocycline in improving functional outcome among patients with acute ischaemic stroke receiving intravenous thrombolysis.Read full original descriptionShow less
Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (EMPHASIS-2): A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial
The aim of this study is to assess the efficacy and safety of minocycline in improving functional outcome among patients with acute ischaemic stroke receiving intravenous thrombolysis.
Inclusion: Age between 18 and 80 years; Patients with acute ischaemic stroke confirmed by CT or MRI; Having received or planning to receive intravenous thrombolysis within 4.5 hours of onset or within an extended window of 4.5-24 hours based on guideline recommendations (The intravenous thrombolytic drugs include: alteplase, tenecteplase, reteplase or recombinant human prourokinase); The study drug can be applied before intravenous thrombolysis or within 2 hours after the initiation of intravenous thrombolysis; 6≤NIHSS≤25, and Ia≤1; Signed informed consent.
Exclusion: mRS score ≥ 2 prior to onset of the current stroke; Presence of a known community-acquired bacterial infection (e.g., pneumonia, urinary tract infection) or any other concurrent infection requiring antibiotic treatment; Use of tretinoin, androgen or antiandrogen treatment (e.g., anabolic steroids, spironolactone) within the past 3 months; History of pseudomembranous colitis or antibiotic-associated colitis; Known allergy or intolerance to tetracycline antibiotics or any component of minocycline; History of intracranial hemorrhagic disease within the past 3 months, for example, parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma; Malformation, tumor, abscess, or other major non-ischaemic brain diseases (e.g., multiple sclerosis, other intracranial space-occupying lesions) on baseline cranial CT or MRI; History of systemic lupus erythematosus; Presence of a severe non-cardio-cerebrovascular disease with a life expectancy of less than 6 months; Any other condition that is not suitable for participating in this clinical trial, such as inability to understand or follow the study procedures due to physical, cognitive, emotional, or mental disorders; Known severe hepatic insufficiency (ALT or AST > 3 times of the upper limit of normal), severe renal insufficiency (creatinine > 3.0 mg/dL [265.2 μmol/L], estimated glomerular filtration rate <30 mL/min/1.73m², or have received dialysis before randomization); Known resistance to other tetracyclines; Use of tetracycline antibiotics within the past 7 days; Rare or unknown etiology of large vessel occlusion (e.g., arterial dissection, vasculitis); Pregnant, breastfeeding, or of childbearing potential who are unwilling to use effective contraception throughout the study; Participation in any other clinical trial within the past 30 days.